{"protocolSection": {"identificationModule": {"nctId": "NCT01786512", "orgStudyIdInfo": {"id": "20110151"}, "secondaryIdInfos": [{"id": "2012-000327-40", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Cytokinetics", "class": "INDUSTRY"}, "briefTitle": "COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure", "officialTitle": "A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With Heart Failure and Left Ventricular Systolic Dysfunction", "acronym": "COSMIC-HF"}, "statusModule": {"statusVerifiedDate": "2021-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-02-26", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-07-22", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-08-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-01-18", "studyFirstSubmitQcDate": "2013-02-06", "studyFirstPostDateStruct": {"date": "2013-02-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-04-23", "resultsFirstSubmitQcDate": "2021-04-23", "resultsFirstPostDateStruct": {"date": "2021-05-17", "type": "ACTUAL"}, "dispFirstSubmitDate": "2016-03-07", "dispFirstSubmitQcDate": "2016-03-07", "dispFirstPostDateStruct": {"date": "2016-04-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-07-25", "lastUpdatePostDateStruct": {"date": "2021-08-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Cytokinetics", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks of treatment.", "detailedDescription": "Omecamtiv mecarbil (AMG 423, CK-1827452) is a novel small molecule that increases cardiac contractility by selectively and directly activating the enzymatic domain of cardiac myosin heavy chain, the force-generating motor protein of the cardiac sarcomere. This is a randomized, placebo-controlled, multicenter, phase 2 study, consisting of a dose escalation phase to select 1 of 3 omecamtiv mecarbil oral formulations in 2 dose escalation cohorts, followed by an expansion phase to evaluate 20 weeks of administration of the selected omecamtiv mecarbil formulation at 2 target dose levels, compared with placebo.\n\nThis study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor."}, "conditionsModule": {"conditions": ["Modified Release Oral Formulation", "Left Ventricular Systolic Dysfunction", "Chronic Heart Failure", "History of Chronic Heart Failure", "Left Ventricular Ejection Fraction", "Pharmacokinetics", "Echocardiogram"], "keywords": ["Pharmacokinetics", "Omecamtiv mecarbil", "AMG 423", "Double-blind", "Randomized", "Placebo-controlled", "Oral forumlation", "CK-1827452", "Cardiac myosin activator"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 544, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dose-escalation Cohort 1: Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo tablets twice a day (BID) for 7 days.", "interventionNames": ["Drug: Placebo"]}, {"label": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "type": "EXPERIMENTAL", "description": "Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days.", "interventionNames": ["Drug: Omecamtiv Mecarbil Matrix F1 Formulation"]}, {"label": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "type": "EXPERIMENTAL", "description": "Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days.", "interventionNames": ["Drug: Omecamtiv Mecarbil Matrix F2 Formulation"]}, {"label": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "type": "EXPERIMENTAL", "description": "Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days.", "interventionNames": ["Drug: Omecamtiv Mecarbil Swellable Core Technology F2"]}, {"label": "Dose-escalation Cohort 2: Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo tablets twice a day for 7 days.", "interventionNames": ["Drug: Placebo"]}, {"label": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "type": "EXPERIMENTAL", "description": "Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days.", "interventionNames": ["Drug: Omecamtiv Mecarbil Matrix F1 Formulation"]}, {"label": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2", "type": "EXPERIMENTAL", "description": "Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days.", "interventionNames": ["Drug: Omecamtiv Mecarbil Matrix F2 Formulation"]}, {"label": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2", "type": "EXPERIMENTAL", "description": "Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days.", "interventionNames": ["Drug: Omecamtiv Mecarbil Swellable Core Technology F2"]}, {"label": "Expansion Phase: Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo tablets twice a day for 20 weeks.", "interventionNames": ["Drug: Placebo"]}, {"label": "Expansion Phase: Omecamtiv Mecarbil 25 mg M-F1", "type": "EXPERIMENTAL", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks.", "interventionNames": ["Drug: Omecamtiv Mecarbil Matrix F1 Formulation"]}, {"label": "Expansion Phase: OM M-F1 PK-based Titration", "type": "EXPERIMENTAL", "description": "All participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL.", "interventionNames": ["Drug: Omecamtiv Mecarbil Matrix F1 Formulation"]}], "interventions": [{"type": "DRUG", "name": "Omecamtiv Mecarbil Matrix F1 Formulation", "description": "Modified release tablets for oral administration", "armGroupLabels": ["Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "Expansion Phase: OM M-F1 PK-based Titration", "Expansion Phase: Omecamtiv Mecarbil 25 mg M-F1"], "otherNames": ["AMG 423", "CK-1827452"]}, {"type": "DRUG", "name": "Omecamtiv Mecarbil Matrix F2 Formulation", "description": "Modified release tablets for oral administration", "armGroupLabels": ["Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2"], "otherNames": ["AMG 423", "CK-1827452"]}, {"type": "DRUG", "name": "Placebo", "description": "Modified release tablets matching to omecamtiv mecarbil", "armGroupLabels": ["Dose-escalation Cohort 1: Placebo", "Dose-escalation Cohort 2: Placebo", "Expansion Phase: Placebo"]}, {"type": "DRUG", "name": "Omecamtiv Mecarbil Swellable Core Technology F2", "description": "Modified release tablets for oral administration", "armGroupLabels": ["Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2"], "otherNames": ["AMG 423", "CK-1827452"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)", "timeFrame": "Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose."}, {"measure": "Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)", "timeFrame": "Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose."}, {"measure": "Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7", "timeFrame": "Day 7 at predose"}, {"measure": "Dose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil", "timeFrame": "Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose"}, {"measure": "Expansion Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing", "timeFrame": "Predose (before morning dose) at weeks 2, 8, 12, 16, and 20"}, {"measure": "Expansion Phase: Maximum Observed Plasma Concentration of Omecamtiv Mecarbil", "timeFrame": "Weeks 2 and 12 at predose and 1, 2, 4, 6, and 8 hours post-dose."}], "secondaryOutcomes": [{"measure": "Expansion Phase: Change From Baseline in Systolic Ejection Time (SET) at Week 20", "description": "Systolic ejection time was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "timeFrame": "Baseline and week 20"}, {"measure": "Expansion Phase: Change From Baseline in Stroke Volume at Week 20", "description": "Stroke volume was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "timeFrame": "Baseline and week 20"}, {"measure": "Expansion Phase: Change From Baseline in Left Ventricular End Systolic Diameter (LVESD) at Week 20", "description": "LVESD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "timeFrame": "Baseline and week 20"}, {"measure": "Expansion Phase: Change From Baseline in Left Ventricular End Diastolic Diameter (LVEDD) at Week 20", "description": "LVEDD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "timeFrame": "Baseline and week 20"}, {"measure": "Expansion Phase: Change From Baseline in Heart Rate at Week 20", "description": "Heart rate was measured using electrocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "timeFrame": "Baseline and week 20"}, {"measure": "Expansion Phase: Change From Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP) at Week 20", "description": "Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "timeFrame": "Baseline and week 20"}, {"measure": "Dose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events", "description": "An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events.\n\nEach adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE.\n\nA serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria:\n\n* fatal\n* life threatening\n* required in-patient hospitalization or prolongation of existing hospitalization\n* resulted in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event", "timeFrame": "From first dose of study drug to 4 weeks after last dose; treatment duration was 7 days in the dose escalation phase."}, {"measure": "Expansion Phase: Number of Participants With Treatment-emergent Adverse Events", "description": "An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events.\n\nEach adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE.\n\nA serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria:\n\n* fatal\n* life threatening\n* required in-patient hospitalization or prolongation of existing hospitalization\n* resulted in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event", "timeFrame": "From first dose of study drug until 4 weeks after last dose; treatment duration was 20 weeks in the expansion phase."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* History of chronic heart failure (HF), defined as requiring treatment for HF for a minimum of 4 weeks prior to screening\n* Treated with stable, optimal pharmacological therapy for \u2265 4 weeks\n* History of left ventricular ejection fraction (LVEF) \u2264 40%\n* Elevated N-terminal prohormone B-type natriuretic peptide (NT-proBNP)\n\nExclusion criteria:\n\n* Severe uncorrected valvular heart disease\n* Hospitalization within 30 days prior to enrollment\n* Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease\n* Acute myocardial infarction, unstable angina or persistent angina at rest within 30 days prior to randomization\n* Systolic blood pressure \\> 160 mmHg or \\< 90 mmHg or diastolic blood pressure \\> 90 mmHg\n* Total bilirubin \u2265 2 x upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \u2265 3 x ULN\n* Estimated glomerular filtration rate (eGFR) \\< 30 mL/min/1.73m\\^2", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "MD", "affiliation": "Amgen", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Mobile", "state": "Alabama", "zip": "36608", "country": "United States", "geoPoint": {"lat": 30.69436, "lon": -88.04305}}, {"facility": "Research Site", "city": "Costa Mesa", "state": "California", "zip": "92626", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Research Site", "city": "Fresno", "state": "California", "zip": "93721", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Research Site", "city": "Inglewood", "state": "California", "zip": "90301", "country": "United States", "geoPoint": {"lat": 33.96168, "lon": -118.35313}}, {"facility": "Research Site", "city": "La Jolla", "state": "California", "zip": "92037", "country": "United States", "geoPoint": {"lat": 32.84727, "lon": -117.2742}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90033", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Thousand Oaks", "state": "California", "zip": "91360", "country": "United States", "geoPoint": {"lat": 34.17056, "lon": -118.83759}}, {"facility": "Research Site", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Research Site", "city": "Danbury", "state": "Connecticut", "zip": "06810", "country": "United States", "geoPoint": {"lat": 41.39482, "lon": -73.45401}}, {"facility": "Research Site", "city": "Newark", "state": "Delaware", "zip": "19718", "country": "United States", "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"facility": "Research Site", "city": "Atlantis", "state": "Florida", "zip": "33462", "country": "United States", "geoPoint": {"lat": 26.5909, "lon": -80.10088}}, {"facility": "Research Site", "city": "Aventura", "state": "Florida", "zip": "33180", "country": "United States", "geoPoint": {"lat": 25.95648, "lon": -80.13921}}, {"facility": "Research Site", "city": "Clearwater", "state": "Florida", "zip": "33756", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "zip": "33606", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Research Site", "city": "Macon", "state": "Georgia", "zip": "31201", "country": "United States", "geoPoint": {"lat": 32.84069, "lon": -83.6324}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Auburn", "state": "Maine", "zip": "04210", "country": "United States", "geoPoint": {"lat": 44.09785, "lon": -70.23117}}, {"facility": "Research Site", "city": "Baltimore", "state": "Maryland", "zip": "21201", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Research Site", "city": "Detroit", "state": "Michigan", "zip": "48202", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "Research Site", "city": "Petoskey", "state": "Michigan", "zip": "49770", "country": "United States", "geoPoint": {"lat": 45.37334, "lon": -84.95533}}, {"facility": "Research Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55415", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Research Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55417", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Las Vegas", "state": "Nevada", "zip": "89128", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10467", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Cortlandt Manor", "state": "New York", "zip": "10567", "country": "United States", "geoPoint": {"lat": 41.29009, "lon": -73.92042}}, {"facility": "Research Site", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}, {"facility": "Research Site", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Portland", "state": "Oregon", "zip": "97239", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Research Site", "city": "Greenville", "state": "South Carolina", "zip": "29605", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Research Site", "city": "Nashville", "state": "Tennessee", "zip": "37232-8802", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Research Site", "city": "Tullahoma", "state": "Tennessee", "zip": "37388", "country": "United States", "geoPoint": {"lat": 35.36202, "lon": -86.20943}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Seattle", "state": "Washington", "zip": "98195", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Research Site", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Research Site", "city": "Darlinghurst", "state": "New South Wales", "zip": "2010", "country": "Australia", "geoPoint": {"lat": -33.87939, "lon": 151.21925}}, {"facility": "Research Site", "city": "Nedlands", "state": "Western Australia", "zip": "6009", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "Research Site", "city": "Antwerpen", "zip": "2020", "country": "Belgium", "geoPoint": {"lat": 51.21989, "lon": 4.40346}}, {"facility": "Research Site", "city": "Bonheiden", "zip": "2820", "country": "Belgium", "geoPoint": {"lat": 51.02261, "lon": 4.54714}}, {"facility": "Research Site", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Research Site", "city": "Ieper", "zip": "8900", "country": "Belgium", "geoPoint": {"lat": 50.85114, "lon": 2.88569}}, {"facility": "Research Site", "city": "Liege", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Research Site", "city": "Kazanlak", "zip": "6100", "country": "Bulgaria", "geoPoint": {"lat": 42.61667, "lon": 25.4}}, {"facility": "Research Site", "city": "Pazardzhik", "zip": "4700", "country": "Bulgaria", "geoPoint": {"lat": 42.2, "lon": 24.33333}}, {"facility": "Research Site", "city": "Plovdiv", "zip": "4002", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"facility": "Research Site", "city": "Sandanski", "zip": "2800", "country": "Bulgaria", "geoPoint": {"lat": 41.56667, "lon": 23.28333}}, {"facility": "Research Site", "city": "Sliven", "zip": "8800", "country": "Bulgaria", "geoPoint": {"lat": 42.68583, "lon": 26.32917}}, {"facility": "Research Site", "city": "Smolyan", "zip": "4400", "country": "Bulgaria", "geoPoint": {"lat": 41.58528, "lon": 24.69194}}, {"facility": "Research Site", "city": "Sofia", "zip": "1527", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Edmonton", "state": "Alberta", "zip": "T6G 2B7", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "Research Site", "city": "Winnipeg", "state": "Manitoba", "zip": "R2H 2A6", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "Research Site", "city": "St. Johns", "state": "Newfoundland and Labrador", "zip": "A1B 3V6", "country": "Canada", "geoPoint": {"lat": 47.56494, "lon": -52.70931}}, {"facility": "Research Site", "city": "Halifax", "state": "Nova Scotia", "zip": "B3H 3A7", "country": "Canada", "geoPoint": {"lat": 44.64533, "lon": -63.57239}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "zip": "K1Y 4W7", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H3G 1A4", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Qu\u00e9bec", "state": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Sherbrooke", "state": "Quebec", "zip": "J1G 2E8", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "Research Site", "city": "Trois Rivieres", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Research Site", "city": "Brno", "zip": "625 00", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Research Site", "city": "Brno", "zip": "636 00", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Research Site", "city": "Olomouc", "zip": "771 11", "country": "Czechia", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "Research Site", "city": "Praha 2", "zip": "128 08", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Praha 4", "zip": "140 21", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Svitavy", "zip": "568 25", "country": "Czechia", "geoPoint": {"lat": 49.75594, "lon": 16.46829}}, {"facility": "Research Site", "city": "Teplice", "zip": "415 29", "country": "Czechia", "geoPoint": {"lat": 50.6404, "lon": 13.82451}}, {"facility": "Research Site", "city": "Bad Krozingen", "zip": "79189", "country": "Germany", "geoPoint": {"lat": 47.91933, "lon": 7.69045}}, {"facility": "Research Site", "city": "Bad Nauheim", "zip": "61231", "country": "Germany", "geoPoint": {"lat": 50.36463, "lon": 8.73859}}, {"facility": "Research Site", "city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Dortmund", "zip": "44137", "country": "Germany", "geoPoint": {"lat": 51.51494, "lon": 7.466}}, {"facility": "Research Site", "city": "Greifswald", "zip": "17475", "country": "Germany", "geoPoint": {"lat": 54.09311, "lon": 13.38786}}, {"facility": "Research Site", "city": "Budapest", "zip": "1027", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Budapest", "zip": "1125", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Budapest", "zip": "1135", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Jaszbereny", "zip": "5100", "country": "Hungary", "geoPoint": {"lat": 47.5, "lon": 19.91667}}, {"facility": "Research Site", "city": "Zalaegerszeg", "zip": "8900", "country": "Hungary", "geoPoint": {"lat": 46.84, "lon": 16.84389}}, {"facility": "Research Site", "city": "Brescia", "zip": "25125", "country": "Italy", "geoPoint": {"lat": 45.53558, "lon": 10.21472}}, {"facility": "Research Site", "city": "Pavia", "zip": "27100", "country": "Italy", "geoPoint": {"lat": 45.19205, "lon": 9.15917}}, {"facility": "Research Site", "city": "Verona", "zip": "37134", "country": "Italy", "geoPoint": {"lat": 45.4299, "lon": 10.98444}}, {"facility": "Research Site", "city": "Kaunas", "zip": "50009", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Research Site", "city": "Vilnius", "zip": "08661", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Research Site", "city": "Amersfoort", "zip": "3813 TZ", "country": "Netherlands", "geoPoint": {"lat": 52.155, "lon": 5.3875}}, {"facility": "Research Site", "city": "Groningen", "zip": "9713 GZ", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Research Site", "city": "Utrecht", "zip": "3584 CX", "country": "Netherlands", "geoPoint": {"lat": 52.09083, "lon": 5.12222}}, {"facility": "Research Site", "city": "Bialystok", "zip": "15-276", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Klodzko", "zip": "57-300", "country": "Poland", "geoPoint": {"lat": 50.43488, "lon": 16.66145}}, {"facility": "Research Site", "city": "Krakow", "zip": "31-202", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Krakow", "zip": "31-501", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Lublin", "zip": "20-954", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Research Site", "city": "Ruda Slaska", "zip": "41-703", "country": "Poland", "geoPoint": {"lat": 50.2584, "lon": 18.85632}}, {"facility": "Research Site", "city": "Warszawa", "zip": "04-256", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Wroclaw", "zip": "50-981", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Dudley", "zip": "DY1 2HQ", "country": "United Kingdom", "geoPoint": {"lat": 52.5, "lon": -2.08333}}, {"facility": "Research Site", "city": "Dundee", "zip": "DD1 9SY", "country": "United Kingdom", "geoPoint": {"lat": 56.46913, "lon": -2.97489}}, {"facility": "Research Site", "city": "Glasgow", "zip": "G11 6NT", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Research Site", "city": "Harrow", "zip": "HA1 3UJ", "country": "United Kingdom", "geoPoint": {"lat": 51.57142, "lon": -0.33371}}, {"facility": "Research Site", "city": "Leicester", "zip": "LE3 9QP", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Research Site", "city": "Liverpool", "zip": "L14 3PE", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Research Site", "city": "London", "zip": "EC1M 6BQ", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}]}, "referencesModule": {"references": [{"pmid": "27914656", "type": "BACKGROUND", "citation": "Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF Jr, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsanyi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N; COSMIC-HF Investigators. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016 Dec 10;388(10062):2895-2903. doi: 10.1016/S0140-6736(16)32049-9. Epub 2016 Dec 1."}, {"pmid": "33826209", "type": "DERIVED", "citation": "Biering-Sorensen T, Minamisawa M, Liu J, Claggett B, Papolos AI, Felker GM, McMurray JJV, Legg JC, Malik FI, Honarpour N, Kurtz CE, Teerlink JR, Solomon SD. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). Eur J Heart Fail. 2021 Jun;23(6):1052-1056. doi: 10.1002/ejhf.2181. Epub 2021 May 5. No abstract available."}, {"pmid": "33176443", "type": "DERIVED", "citation": "Biering-Sorensen T, Minamisawa M, Claggett B, Liu J, Felker GM, McMurray JJV, Malik FI, Abbasi S, Kurtz CE, Teerlink JR, Solomon SD. Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. Circ Heart Fail. 2020 Dec;13(12):e008007. doi: 10.1161/CIRCHEARTFAILURE.120.008007. Epub 2020 Nov 12. No abstract available."}, {"pmid": "33176437", "type": "DERIVED", "citation": "Felker GM, Solomon SD, McMurray JJV, Cleland JGF, Abbasi SA, Malik FI, Zhang H, Globe G, Teerlink JR; COSMIC-HF Investigators. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. Circ Heart Fail. 2020 Dec;13(12):e007814. doi: 10.1161/CIRCHEARTFAILURE.120.007814. Epub 2020 Nov 12."}], "seeAlsoLinks": [{"label": "AmgenTrials clinical trials website", "url": "http://www.amgentrials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "In each of the dose-escalation cohorts participants were randomized equally to receive 1 of the 3 formulations of OM or placebo. In the expansion phase participants were randomized equally to receive 25 mg oral OM twice daily (fixed-dose group), 25 mg oral OM twice daily titrated up to 50 mg twice daily (pharmacokinetic-titration group), or oral placebo. Randomization in both phases was stratified by presence or absence of atrial fibrillation/flutter.", "recruitmentDetails": "Participants with chronic heart failure treated with stable, optimal pharmacological therapy for \u2265 4 weeks were enrolled from February 2013 to March 2015 at 86 centers in 13 countries in Europe, Australia, and North America.\n\nThe study consisted of a dose-escalation phase to select 1 of 3 omecamtiv mecarbil (OM) oral formulations in 2 dose cohorts, and an expansion phase to evaluate 20 weeks of treatment with the selected formulation at 2 target dose levels, compared with placebo.", "groups": [{"id": "FG000", "title": "Dose-escalation Cohort 1: Placebo", "description": "Participants received placebo tablets twice a day (BID) for 7 days."}, {"id": "FG001", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "description": "Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days."}, {"id": "FG002", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "description": "Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days."}, {"id": "FG003", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "description": "Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days."}, {"id": "FG004", "title": "Dose-escalation Cohort 2: Placebo", "description": "Participants received placebo tablets twice a day for 7 days."}, {"id": "FG005", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "description": "Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days."}, {"id": "FG006", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2", "description": "Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days."}, {"id": "FG007", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2", "description": "Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days."}, {"id": "FG008", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks."}, {"id": "FG009", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "FG010", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "13"}, {"groupId": "FG004", "numSubjects": "10"}, {"groupId": "FG005", "numSubjects": "11"}, {"groupId": "FG006", "numSubjects": "12"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "149"}, {"groupId": "FG009", "numSubjects": "150"}, {"groupId": "FG010", "numSubjects": "149"}]}, {"type": "Received Study Treatment", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "13"}, {"groupId": "FG004", "numSubjects": "10"}, {"groupId": "FG005", "numSubjects": "11"}, {"groupId": "FG006", "numSubjects": "11"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "149"}, {"groupId": "FG009", "numSubjects": "150"}, {"groupId": "FG010", "numSubjects": "146"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "13"}, {"groupId": "FG004", "numSubjects": "10"}, {"groupId": "FG005", "numSubjects": "11"}, {"groupId": "FG006", "numSubjects": "11"}, {"groupId": "FG007", "numSubjects": "14"}, {"groupId": "FG008", "numSubjects": "145"}, {"groupId": "FG009", "numSubjects": "145"}, {"groupId": "FG010", "numSubjects": "137"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "5"}, {"groupId": "FG010", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "1"}, {"groupId": "FG010", "numSubjects": "0"}]}, {"type": "Decision by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}, {"groupId": "FG010", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "3"}, {"groupId": "FG010", "numSubjects": "7"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "4"}, {"groupId": "FG009", "numSubjects": "1"}, {"groupId": "FG010", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Dose-escalation Cohort 1: Placebo", "description": "Participants received placebo tablets twice a day (BID) for 7 days."}, {"id": "BG001", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "description": "Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days."}, {"id": "BG002", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "description": "Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days."}, {"id": "BG003", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "description": "Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days."}, {"id": "BG004", "title": "Dose-escalation Cohort 2: Placebo", "description": "Participants received placebo tablets twice a day for 7 days."}, {"id": "BG005", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "description": "Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days."}, {"id": "BG006", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2", "description": "Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days."}, {"id": "BG007", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2", "description": "Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days."}, {"id": "BG008", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks."}, {"id": "BG009", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "BG010", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}, {"id": "BG011", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "13"}, {"groupId": "BG004", "value": "10"}, {"groupId": "BG005", "value": "11"}, {"groupId": "BG006", "value": "12"}, {"groupId": "BG007", "value": "14"}, {"groupId": "BG008", "value": "149"}, {"groupId": "BG009", "value": "150"}, {"groupId": "BG010", "value": "149"}, {"groupId": "BG011", "value": "544"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "66.5", "spread": "4.6"}, {"groupId": "BG001", "value": "67.7", "spread": "11.4"}, {"groupId": "BG002", "value": "65.3", "spread": "8.8"}, {"groupId": "BG003", "value": "66.7", "spread": "8.7"}, {"groupId": "BG004", "value": "62.1", "spread": "9.3"}, {"groupId": "BG005", "value": "65.1", "spread": "7.0"}, {"groupId": "BG006", "value": "63.8", "spread": "11.6"}, {"groupId": "BG007", "value": "64.3", "spread": "11.5"}, {"groupId": "BG008", "value": "63.7", "spread": "9.7"}, {"groupId": "BG009", "value": "62.8", "spread": "10.2"}, {"groupId": "BG010", "value": "62.7", "spread": "11.7"}, {"groupId": "BG011", "value": "63.4", "spread": "10.4"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "18 - 64 years", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "5"}, {"groupId": "BG005", "value": "6"}, {"groupId": "BG006", "value": "5"}, {"groupId": "BG007", "value": "6"}, {"groupId": "BG008", "value": "82"}, {"groupId": "BG009", "value": "81"}, {"groupId": "BG010", "value": "76"}, {"groupId": "BG011", "value": "280"}]}, {"title": "65 - 74 years", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "5"}, {"groupId": "BG005", "value": "4"}, {"groupId": "BG006", "value": "4"}, {"groupId": "BG007", "value": "5"}, {"groupId": "BG008", "value": "46"}, {"groupId": "BG009", "value": "52"}, {"groupId": "BG010", "value": "50"}, {"groupId": "BG011", "value": "188"}]}, {"title": "75 - 84 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "1"}, {"groupId": "BG006", "value": "3"}, {"groupId": "BG007", "value": "3"}, {"groupId": "BG008", "value": "21"}, {"groupId": "BG009", "value": "17"}, {"groupId": "BG010", "value": "23"}, {"groupId": "BG011", "value": "76"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "3"}, {"groupId": "BG005", "value": "3"}, {"groupId": "BG006", "value": "4"}, {"groupId": "BG007", "value": "2"}, {"groupId": "BG008", "value": "30"}, {"groupId": "BG009", "value": "23"}, {"groupId": "BG010", "value": "24"}, {"groupId": "BG011", "value": "97"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "7"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "8"}, {"groupId": "BG007", "value": "12"}, {"groupId": "BG008", "value": "119"}, {"groupId": "BG009", "value": "127"}, {"groupId": "BG010", "value": "125"}, {"groupId": "BG011", "value": "447"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "1"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "2"}, {"groupId": "BG009", "value": "7"}, {"groupId": "BG010", "value": "4"}, {"groupId": "BG011", "value": "17"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "9"}, {"groupId": "BG005", "value": "11"}, {"groupId": "BG006", "value": "11"}, {"groupId": "BG007", "value": "14"}, {"groupId": "BG008", "value": "147"}, {"groupId": "BG009", "value": "143"}, {"groupId": "BG010", "value": "145"}, {"groupId": "BG011", "value": "527"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}, {"groupId": "BG011", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}, {"groupId": "BG011", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "2"}, {"groupId": "BG009", "value": "1"}, {"groupId": "BG010", "value": "0"}, {"groupId": "BG011", "value": "3"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "3"}, {"groupId": "BG006", "value": "1"}, {"groupId": "BG007", "value": "2"}, {"groupId": "BG008", "value": "11"}, {"groupId": "BG009", "value": "5"}, {"groupId": "BG010", "value": "8"}, {"groupId": "BG011", "value": "34"}]}, {"title": "Mixed Race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}, {"groupId": "BG011", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "1"}, {"groupId": "BG010", "value": "0"}, {"groupId": "BG011", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "10"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "11"}, {"groupId": "BG007", "value": "12"}, {"groupId": "BG008", "value": "136"}, {"groupId": "BG009", "value": "142"}, {"groupId": "BG010", "value": "140"}, {"groupId": "BG011", "value": "502"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "1"}, {"groupId": "BG010", "value": "1"}, {"groupId": "BG011", "value": "3"}]}]}]}, {"title": "Stratification Factor - Atrial Fibrillation/Flutter at Randomization", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "1"}, {"groupId": "BG006", "value": "2"}, {"groupId": "BG007", "value": "3"}, {"groupId": "BG008", "value": "32"}, {"groupId": "BG009", "value": "32"}, {"groupId": "BG010", "value": "32"}, {"groupId": "BG011", "value": "107"}]}, {"title": "No", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "10"}, {"groupId": "BG005", "value": "10"}, {"groupId": "BG006", "value": "10"}, {"groupId": "BG007", "value": "11"}, {"groupId": "BG008", "value": "117"}, {"groupId": "BG009", "value": "118"}, {"groupId": "BG010", "value": "117"}, {"groupId": "BG011", "value": "437"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)", "populationDescription": "The pharmacokinetic analysis set (PKAS) included all randomized participants who received at least 1 dose of OM and had at least 1 evaluable OM PK parameter.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose.", "groups": [{"id": "OG000", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "description": "Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days."}, {"id": "OG001", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "description": "Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days."}, {"id": "OG002", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "description": "Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days."}, {"id": "OG003", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "description": "Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days."}, {"id": "OG004", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2", "description": "Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days."}, {"id": "OG005", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2", "description": "Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "193", "spread": "58.8"}, {"groupId": "OG001", "value": "201", "spread": "94.4"}, {"groupId": "OG002", "value": "171", "spread": "53.8"}, {"groupId": "OG003", "value": "492", "spread": "115"}, {"groupId": "OG004", "value": "502", "spread": "138"}, {"groupId": "OG005", "value": "601", "spread": "204"}]}]}]}, {"type": "PRIMARY", "title": "Dose Escalation Phase: Time to Maximum Observed Plasma Concentration (Tmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7)", "populationDescription": "Pharmacokinetic analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hours", "timeFrame": "Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours, and 7 days post-dose.", "groups": [{"id": "OG000", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "description": "Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days."}, {"id": "OG001", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "description": "Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days."}, {"id": "OG002", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "description": "Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days."}, {"id": "OG003", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "description": "Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days."}, {"id": "OG004", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2", "description": "Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days."}, {"id": "OG005", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2", "description": "Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.9", "spread": "4.4"}, {"groupId": "OG001", "value": "2.0", "spread": "1.2"}, {"groupId": "OG002", "value": "4.2", "spread": "1.9"}, {"groupId": "OG003", "value": "2.6", "spread": "2.4"}, {"groupId": "OG004", "value": "2.2", "spread": "1.8"}, {"groupId": "OG005", "value": "4.6", "spread": "2.3"}]}]}]}, {"type": "PRIMARY", "title": "Dose Escalation Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing on Day 7", "populationDescription": "Pharmacokinetic analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 7 at predose", "groups": [{"id": "OG000", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "description": "Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days."}, {"id": "OG001", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "description": "Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days."}, {"id": "OG002", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "description": "Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days."}, {"id": "OG003", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "description": "Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days."}, {"id": "OG004", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2", "description": "Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days."}, {"id": "OG005", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2", "description": "Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "157", "spread": "63.7"}, {"groupId": "OG001", "value": "137", "spread": "56.8"}, {"groupId": "OG002", "value": "134", "spread": "54.7"}, {"groupId": "OG003", "value": "376", "spread": "170"}, {"groupId": "OG004", "value": "395", "spread": "108"}, {"groupId": "OG005", "value": "476", "spread": "234"}]}]}]}, {"type": "PRIMARY", "title": "Dose Escalation Phase: Area Under the Plasma Concentration-time Curve for a Dosing Interval of 12 Hours Post Dose (AUC12) for Omecamtiv Mecarbil", "populationDescription": "Pharmacokinetic analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Day 7 at predose and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post-dose", "groups": [{"id": "OG000", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "description": "Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days."}, {"id": "OG001", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "description": "Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days."}, {"id": "OG002", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "description": "Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days."}, {"id": "OG003", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "description": "Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days."}, {"id": "OG004", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2", "description": "Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days."}, {"id": "OG005", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2", "description": "Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "13"}, {"groupId": "OG003", "value": "10"}, {"groupId": "OG004", "value": "11"}, {"groupId": "OG005", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2030", "spread": "658"}, {"groupId": "OG001", "value": "2000", "spread": "1020"}, {"groupId": "OG002", "value": "1740", "spread": "586"}, {"groupId": "OG003", "value": "5070", "spread": "1060"}, {"groupId": "OG004", "value": "5010", "spread": "1160"}, {"groupId": "OG005", "value": "6550", "spread": "2340"}]}]}]}, {"type": "PRIMARY", "title": "Expansion Phase: Plasma Concentration of Omecamtiv Mecarbil Prior to Dosing", "populationDescription": "Pharmacokinetic analysis set with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Predose (before morning dose) at weeks 2, 8, 12, 16, and 20", "groups": [{"id": "OG000", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "OG001", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "141"}]}], "classes": [{"title": "Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "136"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "174", "spread": "62.2"}, {"groupId": "OG001", "value": "179", "spread": "68.8"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "130"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "156", "spread": "69.1"}, {"groupId": "OG001", "value": "161", "spread": "74.4"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "165", "spread": "67.9"}, {"groupId": "OG001", "value": "263", "spread": "116"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "119"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "155", "spread": "69.0"}, {"groupId": "OG001", "value": "240", "spread": "120"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "121"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "149", "spread": "71.2"}, {"groupId": "OG001", "value": "239", "spread": "118"}]}]}]}, {"type": "PRIMARY", "title": "Expansion Phase: Maximum Observed Plasma Concentration of Omecamtiv Mecarbil", "populationDescription": "Pharmacokinetic analysis set with available data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Weeks 2 and 12 at predose and 1, 2, 4, 6, and 8 hours post-dose.", "groups": [{"id": "OG000", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "OG001", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "141"}]}], "classes": [{"title": "Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "141"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "212", "spread": "70.4"}, {"groupId": "OG001", "value": "212", "spread": "81.0"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "137"}, {"groupId": "OG001", "value": "127"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "200", "spread": "71.1"}, {"groupId": "OG001", "value": "318", "spread": "129"}]}]}]}, {"type": "SECONDARY", "title": "Expansion Phase: Change From Baseline in Systolic Ejection Time (SET) at Week 20", "description": "Systolic ejection time was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "populationDescription": "The full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug. The repeated-measures model included all observed values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "seconds", "timeFrame": "Baseline and week 20", "groups": [{"id": "OG000", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks."}, {"id": "OG001", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "OG002", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0000", "spread": "0.0025"}, {"groupId": "OG001", "value": "0.0112", "spread": "0.0024"}, {"groupId": "OG002", "value": "0.0250", "spread": "0.0026"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.0007", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "0.0112", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.0047", "ciUpperLimit": "0.0176", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0033", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "<0.0001", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "0.0250", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.0184", "ciUpperLimit": "0.0315", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0033", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}]}, {"type": "SECONDARY", "title": "Expansion Phase: Change From Baseline in Stroke Volume at Week 20", "description": "Stroke volume was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "populationDescription": "The full analysis set included all randomized participants who received at least 1 dose of study drug. The repeated-measures model included all observed values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mL", "timeFrame": "Baseline and week 20", "groups": [{"id": "OG000", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks."}, {"id": "OG001", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "OG002", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.05", "spread": "1.18"}, {"groupId": "OG001", "value": "3.53", "spread": "1.16"}, {"groupId": "OG002", "value": "2.58", "spread": "1.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.0036", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "4.58", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.50", "ciUpperLimit": "7.65", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.56", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.0217", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "3.63", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.53", "ciUpperLimit": "6.72", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.57", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}]}, {"type": "SECONDARY", "title": "Expansion Phase: Change From Baseline in Left Ventricular End Systolic Diameter (LVESD) at Week 20", "description": "LVESD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "populationDescription": "The full analysis set included all randomized participants who received at least 1 dose of study drug. The repeated-measures model included all observed values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm", "timeFrame": "Baseline and week 20", "groups": [{"id": "OG000", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks."}, {"id": "OG001", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "OG002", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.242", "spread": "0.043"}, {"groupId": "OG001", "value": "-0.322", "spread": "0.044"}, {"groupId": "OG002", "value": "-0.421", "spread": "0.045"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.1732", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "-0.079", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.194", "ciUpperLimit": "0.035", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.058", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.0027", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "-0.179", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.295", "ciUpperLimit": "-0.062", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.059", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}]}, {"type": "SECONDARY", "title": "Expansion Phase: Change From Baseline in Left Ventricular End Diastolic Diameter (LVEDD) at Week 20", "description": "LVEDD was measured using echocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "populationDescription": "The full analysis set included all randomized participants who received at least 1 dose of study drug. The repeated-measures model included all observed values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm", "timeFrame": "Baseline and week 20", "groups": [{"id": "OG000", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks."}, {"id": "OG001", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "OG002", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.089", "spread": "0.038"}, {"groupId": "OG001", "value": "0.023", "spread": "0.038"}, {"groupId": "OG002", "value": "-0.040", "spread": "0.040"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.1899", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "-0.067", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.166", "ciUpperLimit": "0.033", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.051", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.0128", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "-0.129", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.231", "ciUpperLimit": "-0.028", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.052", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}]}, {"type": "SECONDARY", "title": "Expansion Phase: Change From Baseline in Heart Rate at Week 20", "description": "Heart rate was measured using electrocardiography. Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "populationDescription": "The full analysis set included all randomized participants who received at least 1 dose of study drug. The repeated-measures model included all observed values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "bpm", "timeFrame": "Baseline and week 20", "groups": [{"id": "OG000", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks."}, {"id": "OG001", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "OG002", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.57", "spread": "0.79"}, {"groupId": "OG001", "value": "-0.77", "spread": "0.79"}, {"groupId": "OG002", "value": "-2.40", "spread": "0.81"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.2177", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "-1.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.47", "ciUpperLimit": "0.79", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.09", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.0070", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "-2.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.12", "ciUpperLimit": "-0.81", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.09", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}]}, {"type": "SECONDARY", "title": "Expansion Phase: Change From Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP) at Week 20", "description": "Least squares means are from a repeated measures model including treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates.", "populationDescription": "The full analysis set included all randomized participants who received at least 1 dose of study drug. The repeated-measures model included all observed values.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline and week 20", "groups": [{"id": "OG000", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks."}, {"id": "OG001", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "OG002", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "502", "spread": "257"}, {"groupId": "OG001", "value": "-319", "spread": "257"}, {"groupId": "OG002", "value": "-468", "spread": "262"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.0205", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "-822", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1516", "ciUpperLimit": "-127", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "353", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.0069", "statisticalMethod": "Repeated Measures", "paramType": "Treatment difference", "paramValue": "-970", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1672", "ciUpperLimit": "-268", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "357", "estimateComment": "Repeated measures model includes treatment group, stratification factor, scheduled visit, interaction of treatment with scheduled visit and the baseline value as covariates."}]}, {"type": "SECONDARY", "title": "Dose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events", "description": "An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events.\n\nEach adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE.\n\nA serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria:\n\n* fatal\n* life threatening\n* required in-patient hospitalization or prolongation of existing hospitalization\n* resulted in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event", "populationDescription": "Participants randomized in the dose-escalation phase who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From first dose of study drug to 4 weeks after last dose; treatment duration was 7 days in the dose escalation phase.", "groups": [{"id": "OG000", "title": "Dose-escalation Cohort 1: Placebo", "description": "Participants received placebo tablets twice a day (BID) for 7 days."}, {"id": "OG001", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "description": "Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days."}, {"id": "OG002", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "description": "Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days."}, {"id": "OG003", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "description": "Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days."}, {"id": "OG004", "title": "Dose-escalation Cohort 2: Placebo", "description": "Participants received placebo tablets twice a day for 7 days."}, {"id": "OG005", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "description": "Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days."}, {"id": "OG006", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2", "description": "Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days."}, {"id": "OG007", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2", "description": "Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "13"}, {"groupId": "OG004", "value": "10"}, {"groupId": "OG005", "value": "11"}, {"groupId": "OG006", "value": "11"}, {"groupId": "OG007", "value": "14"}]}], "classes": [{"title": "Any treatment-emergent adverse event (TEAE)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "9"}, {"groupId": "OG006", "value": "3"}, {"groupId": "OG007", "value": "5"}]}]}, {"title": "TEAE Grade \u2265 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "5"}, {"groupId": "OG006", "value": "1"}, {"groupId": "OG007", "value": "1"}]}]}, {"title": "TEAE Grade \u2265 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "1"}]}]}, {"title": "TEAE Grade \u2265 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Serious adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "1"}]}]}, {"title": "TEAE leading to discontinuation of study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "2"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}, {"title": "Fatal adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Expansion Phase: Number of Participants With Treatment-emergent Adverse Events", "description": "An adverse event is defined as any untoward medical occurrence in a clinical trial participant, including worsening of a preexisting medical condition. The event does not necessarily have a causal relationship with study treatment. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events.\n\nEach adverse event was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, and Grade 4 = life-threatening AE.\n\nA serious adverse event is defined as an adverse event that met at least 1 of the following serious criteria:\n\n* fatal\n* life threatening\n* required in-patient hospitalization or prolongation of existing hospitalization\n* resulted in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event", "populationDescription": "All participants randomized in the expansion phase who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From first dose of study drug until 4 weeks after last dose; treatment duration was 20 weeks in the expansion phase.", "groups": [{"id": "OG000", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks."}, {"id": "OG001", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks."}, {"id": "OG002", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"title": "Any treatment-emergent adverse event (TEAE)", "categories": [{"measurements": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "92"}, {"groupId": "OG002", "value": "95"}]}]}, {"title": "TEAE Grade \u2265 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "61"}]}]}, {"title": "TEAE Grade \u2265 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "34"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "31"}]}]}, {"title": "TEAE Grade \u2265 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "Serious adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "32"}]}]}, {"title": "TEAEs leading to discontinuation of study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": "Fatal adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first dose of study drug to 4 weeks after last dose; treatment duration was 7 days in the dose escalation phase and 20 weeks in the expansion phase.", "description": "Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Dose-escalation Cohort 1: Placebo", "description": "Participants received placebo tablets BID for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 4, "otherNumAtRisk": 11}, {"id": "EG001", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1", "description": "Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 2, "otherNumAtRisk": 10}, {"id": "EG002", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2", "description": "Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days.", "seriousNumAffected": 1, "seriousNumAtRisk": 14, "otherNumAffected": 5, "otherNumAtRisk": 14}, {"id": "EG003", "title": "Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2", "description": "Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 6, "otherNumAtRisk": 13}, {"id": "EG004", "title": "Dose-escalation Cohort 2: Placebo", "description": "Participants received placebo tablets twice a day for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 1, "otherNumAtRisk": 10}, {"id": "EG005", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1", "description": "Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days.", "seriousNumAffected": 2, "seriousNumAtRisk": 11, "otherNumAffected": 8, "otherNumAtRisk": 11}, {"id": "EG006", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2", "description": "Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 3, "otherNumAtRisk": 11}, {"id": "EG007", "title": "Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2", "description": "Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days.", "seriousNumAffected": 1, "seriousNumAtRisk": 14, "otherNumAffected": 4, "otherNumAtRisk": 14}, {"id": "EG008", "title": "Expansion Phase: Placebo", "description": "Participants received placebo tablets twice a day for 20 weeks.", "seriousNumAffected": 30, "seriousNumAtRisk": 149, "otherNumAffected": 48, "otherNumAtRisk": 149}, {"id": "EG009", "title": "Expansion Phase: Omecamtiv Mecarbil 25 mg", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks.", "seriousNumAffected": 36, "seriousNumAtRisk": 150, "otherNumAffected": 51, "otherNumAtRisk": 150}, {"id": "EG010", "title": "Expansion Phase: OM PK-based Titration", "description": "Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL.", "seriousNumAffected": 32, "seriousNumAtRisk": 146, "otherNumAffected": 48, "otherNumAtRisk": 146}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Cardiac asthma", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 5, "numAtRisk": 146}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 3, "numAtRisk": 146}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 3, "numAtRisk": 146}]}, {"term": "Cardio-respiratory distress", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Ischaemic cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Left ventricular dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Pericardial effusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Vertigo positional", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Cardiac complication associated with device", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Impaired healing", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Hepatic congestion", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Hepatic failure", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Abscess limb", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Arthritis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Bronchopneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 2, "numAtRisk": 146}]}, {"term": "Gangrene", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Klebsiella sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 3, "numAtRisk": 146}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Prostate infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Urinary tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Ulnar nerve injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Vascular pseudoaneurysm", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Troponin I increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Troponin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 2, "numAtRisk": 146}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Bladder cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Carcinoma in situ of skin", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Metastases to central nervous system", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Metastatic carcinoma of the bladder", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Tonsil cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Facial paresis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Ischaemic cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Myoclonus", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Chronic kidney disease", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Decubitus ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Bundle branch block left", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 9, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 3, "numAtRisk": 146}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 4, "numAtRisk": 146}]}, {"term": "Sinus bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Sinus tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Tinnitus", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Abnormal faeces", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 5, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 5, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 4, "numAtRisk": 146}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 5, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 8, "numAtRisk": 146}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 2, "numAtRisk": 146}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 14, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 9, "numAtRisk": 146}]}, {"term": "Feeling hot", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Nodule", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 5, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 8, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 5, "numAtRisk": 146}]}, {"term": "Skin abrasion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Blood alkaline phosphatase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Blood bicarbonate decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Carotid bruit", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Heart rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "N-terminal prohormone brain natriuretic peptide increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Troponin I increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 6, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 2, "numAtRisk": 146}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 6, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 8, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 9, "numAtRisk": 146}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 5, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 9, "numAtRisk": 146}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Mental status changes", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 7, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 9, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 13, "numAtRisk": 146}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 2, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 2, "numAtRisk": 146}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 0, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 0, "numAtRisk": 146}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 3, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 5, "numAtRisk": 146}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG006", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG007", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG008", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG009", "numAffected": 1, "numAtRisk": 150}, {"groupId": "EG010", "numAffected": 1, "numAtRisk": 146}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication."}, "pointOfContact": {"title": "Study Director", "organization": "Amgen Inc.", "email": "medinfo@amgen.com", "phone": "866-572-6436"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000018487", "term": "Ventricular Dysfunction, Left"}, {"id": "D000054160", "term": "Systolic Murmurs"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006337", "term": "Heart Murmurs"}, {"id": "D000018754", "term": "Ventricular Dysfunction"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "asFound": "Systolic", "relevance": "HIGH"}, {"id": "M20824", "name": "Ventricular Dysfunction", "relevance": "LOW"}, {"id": "M20591", "name": "Ventricular Dysfunction, Left", "asFound": "Left Ventricular Systolic Dysfunction", "relevance": "HIGH"}, {"id": "M9425", "name": "Heart Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "asFound": "Chronic", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}